BioCentury | Dec 14, 2018
Clinical News

Netris' NTN1 inhibitor safe in Phase I for solid tumors

...Netris Pharma S.A.S. (Lyon, France) said escalating doses of up to 20 mg/kg IV NP137 every...
...pretreated advanced solid tumors. The company said two patients with advanced uterine cancer who received NP137...
...a medical meeting. The expansion portion of the open-label, French trial is enrolling 24 patients. NP137...
BioCentury | Aug 19, 2017
Product Development

Restoring dependence

...cells. By February, the company expects to have data from a Phase I trial of NP137...
...receptors’ ligands. Netris antibodies bind the ligands and prevent them from interacting with their receptors. NP137...
...preclinical data showed that in a breast cancer model, roughly two-thirds of mice given received NP137...
BioCentury | Mar 29, 2017
Clinical News

NP137: Ph I started

...Netris began an open-label, 2-part, French Phase I trial to evaluate IV NP137 given every other...
...part 1 will evaluate 1, 2, 4, 6, 9, 14 and 20 mg/kg doses of NP137...
...will be evaluated in the expansion part 2. Netris Pharma S.A.S. , Lyon, France Product: NP137...
Items per page:
1 - 3 of 3